Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 855-862

  Utsuki, Tada ^a,b   Yu, Qian Sheng ^b   Davidson, Diane ^c   Chen, Demao ^d   Holloway, Harold W ^b   Brossi, Arnold ^e   Sambamurti, Kumar ^f   Lahiri, Debomoy K ^d   Greig, Nigel H ^b   Giordano, Tony ^a,c  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Message Pharmaceuticals Inc   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' BROMO PHENSERINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DRUG ANALOG; ESEROLINE; N DIMETHYL, N1 BENZYL SEROTONIN; N1 BENZYL, 4' BENZYLOXY PHENSERINE; N1 BENZYL, N8 NOR,4' ISOPROPYL PHENSERINE; N1 PHENETHYL,4' ISOPROPYL PHENSERINE; N1,N8 DIBENZYL PHENSERINE; N8 BENZYL PHENSERINE; PHENSERINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHOLINERGIC ACTIVITY; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG INHIBITION; ENANTIOMER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PHYSOSTIGMINE; RNA, MESSENGER; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745966453     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103309     Document Type: Article

References (40)

1. Brun S, Faucon-Biguet N, and Mallet J (2003) Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol Ther 7:782-789.
2. Chauhan NB and Siegel GJ (2003) Intracerebroventricular passive immunization with anti-Ab antibody in Tg2576. J Neurosci Res 74:142-147.
3. Dancey J (2002) Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16:1101-1114.
4. DeKosky STSS (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27:457-464.
5. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, and Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-298.
6. Gingras A-C, Raught B, and Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913-963.
7. Greig NH, Pei X, Soncrant TT, Ingram DK, and Brossi A (1995) Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev 15:3-31.
8. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, and Lahiri DK (2005a) An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2:281-290.
9. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu QS, Mamczarz J, Holloway HW, Giordano T, et al. (2005b) Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 102:17213-17218.
10. Haghighat A, Mader S, Pause A, and Sonenberg N (1995) Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO (Eur Mol Biol Organ) J 14:5701-5709.
11. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, and Wallace WC (1997) Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res 46:161-168.
12. Huang S and Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371-377.
13. Jacinto EHM (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117-126.
14. Kelleher I, Raymond J, Govindarajan A, and Tonegawa S (2004a) Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 44:59-73.
15. Kelleher R, Govindarajan A, Jung H, Kang H, and Tonegawa S (2004b) Translational control by MAPK signaling in long-term synaptic plasticity and memory. Neuron 116:467-479.
16. Krichevsky A and Kosik K (2001) Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 32:683-696.
17. LaFerla FM and Oddo S (2005) Alzheimer's disease: A[beta], tau and synaptic dysfunction. Trends Mol Med 11:170-176.
18. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, et al. (2004) Alzheimer's disease A{beta} vaccine reduces central nervous system a{beta} levels in a non-human primate, the Caribbean vervet. Am J Pathol 165:283-297.
19. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, and Hyman BT (2003) Amyloid-{beta} antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23:10879-10883.
20. Malter JS (2001) Regulation of mRNA stability in the nervous system and beyond: mini review. J Neurosci Res 66:311-316.
21. Mbongolo Mbella EG, Bertrand S, Huex G, and Octave J-N (2000) A GG nucleotide sequence of the 3′ untranslated region of amyloid precursor protein mRNA plays a key role in the regulation of translation and the binding of proteins. Mol Cell Biol 20:4572-4579.
22. Morgan C, Colombres M, Nunez MT, and Inestrosa NC (2004) Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 74:323-349.
23. Morse L, Payton SM, Cuny GD, and Rogers JT (2004) FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci 24:129-136.
24. Nicoll J, Wilkinson D, Holmes C, Steart P, Markham H, and Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452
25. Pakaski M and Kasa P (2003) Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disorders 2:163-171.
26. Racchi M, Mazzucchelli M, Porrello E, Lanni C, and Govoni S (2004) Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacol Res 50:441-451.
27. Reinhard C, Hebert SS, and De Strooper B (2005) The amyloid-beta precursor protein: integrating structure with biological function. EMBO (Eur Mol Biol Organ) J 24:3996-4006.
28. Rhoads RE (1999) Minireview: signal transduction pathways that regulate eukaryotic protein synthesis. J Biol Chem 274:30337-30340.
29. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan S-S, Potter H, and Nilsson LNG (1999) Translation of the Alzheimer amyloid precursor protein mRNA is upregulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274:6421-6431.
30. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, et al. (2002a) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277:45518-45528.
31. Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, et al. (2002b) Alzheimer's disease drug discovery targeted to the APP mRNA 5′ untranslated region. J Mol Neurosci 19:77-82.
32. Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, and Greig NH (2006) A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 3:81-90.
33. Shaw KTY, Utsuki T, Rogers J, Yu Q-S, Sambamurti K, Brossi A, Ge Y-W, Lahiri DK, and Greig NH (2001) Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci USA 98:7605-7610.
34. Steward O and Schuman EM (2001) Protein synthesis at synaptic sites on dendrites. Annu Rev Neurosci 24:299-325.
35. Steward O and Schuman EM (2003) Compartmentalized synthesis and degradation of proteins in neurons. Neuron 40:347-359.
36. Sze CITJ, Kawas C, Mouton P, Price DL, and Martin LJ (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933-944.
37. Tabuchu A, Ishii A, Fukuchi M, Kobayashi S, Suzuki T, and Tsuda M (2004) Activity-dependent increase in B-amyloid precursor protein mRNA expression in neurons. Neuroreport 15:1329-1333.
38. Tang SJ, Reis G, Kang H, Gingras A-C, Sonenberg N, and Schuman EM (2002) A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci 99:467-472.
39. Wallace W, Lieberburg I, Schenk D, Vigo-Pelfrey C, Davis K, and Haroutunian V (1995) Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats and its exacerbation in aged rats. J Neurosci 15:4896-4905.
40. Younkin S (2001) Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med 7:18-19.